Pancreatic Cancer Trials
Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Rainier™ is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with Abraxane® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Rainier is designed to evaluate the potential benefit of adding apatorsen to Abraxane and gemcitabine therapy by measuring the treatments’ impact on survival. The trial is sponsored by the Sarah Cannon Research Institute (SCRI).
Enrollment Completed. Learn more about the Rainier Trial